Clinical Trials on Local Advanced High Risk Nasopharyngeal Carcinoma

Total 116 results

Zhao Chong
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Jiangxi... and other collaborators

Completed

Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

Local Advanced High Risk Nasopharyngeal Carcinoma

China
Sun Yat-sen University

Active, not recruiting

Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients

Local Advanced High Risk Nasopharyngeal Carcinoma

China
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Jiangxi Provincial Cancer Hospital

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer

China
West China Hospital

Recruiting

Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors (TNTCRT)

Chemoradiotherapy | Total Neoadjuvant Treatment | Local Advanced Rectal Cancer | High Risk Factors

China
Gustave Roussy, Cancer Campus, Grand Paris

Unknown

PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE.

LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE UCNT

France
Guiyang Medical University

Unknown

GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Chinese University of Hong Kong

Completed

New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer

Advanced Nasopharyngeal Carcinoma

Hong Kong
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC

Advanced Nasopharyngeal Carcinoma

China
Zhejiang Cancer Hospital
Zhejiang Provincial People's Hospital; The Central Hospital of Lishui City; First... and other collaborators

Recruiting

Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma (IRCNPC)

Locally Advanced Nasopharyngeal Carcinoma

China
Guiyang Medical University

Unknown

GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Locally Advanced Nasopharyngeal Carcinoma

China
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

China
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

China
Yonsei University

Not yet recruiting

A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma

Korea, Republic of
Guiyang Medical University

Recruiting

TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Locally Advanced Nasopharyngeal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University

Completed

Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma (FMTN-I-LNPC)

Locally Advanced Nasopharyngeal Carcinoma

China
Ospedale Santa Croce-Carle Cuneo

Unknown

Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies

Advanced Haematological Malignancies | High Risk Haematological Malignancies

Italy
Sun Yat-sen University

Recruiting

Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Induction Chemotherapy | Locally Advanced Nasopharyngeal Carcinoma | PD-L1 | Envafolimab

China
Lawson Health Research Institute

Recruiting

Three Fraction Radiation to Induce Immuno-Oncologic Response (TRIO)

Locally Advanced Breast Cancer | High-Risk Cancer

Canada
University of Pittsburgh

Terminated

Comparison of Elective Lymph Node Treatment Versus Clinical Observation in the Absence of Palpable Lymph Nodes for High Risk Skin Squamous Cell Carcinoma (SCC)

High Risk Cutaneous Squamous Cell Carcinoma

United States
Guiyang Medical University

Unknown

the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
First Affiliated Hospital of Guangxi Medical University
Zhejiang Cancer Hospital; Guilin Medical University, China; Liuzhou Workers Hospital and other collaborators

Not yet recruiting

Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy

Locally Advanced Nasopharyngeal Carcinoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Unresectable Head and Neck Squamous Cell Carcinoma | Unresectable Oropharyngeal... and other conditions

United States
Emory University
Astex Pharmaceuticals, Inc.

Recruiting

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Head and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...

United States
BeiGene

Active, not recruiting

Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma (HNSCC) | Nasopharyngeal Carcinoma (NPC)

Canada, Australia, New Zealand, Korea, Republic of, United States, Malaysia, Thailand
RenJi Hospital

Completed

Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma

China
Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
AstraZeneca

Completed

Non-Interventional Study PREVENT (PREVENT)

Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients

Russian Federation
Nanfang Hospital, Southern Medical University
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer

Rectal Cancer | MSS | Locally Advanced | High-Risk

China
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Breast Cancer | Early-stage Breast Cancer | High Risk Breast Carcinoma

United States
Henan Cancer Hospital

Recruiting

Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma

Intraoperative Complications | Perfusion; Complications | High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Cancer Trials Ireland
Janssen, LP

Completed

Neo-adjuvant Abiraterone Prostate Study

High Risk Localised Prostate Carcinoma

Ireland
Lei Li

Unknown

DNA Methylation Testing for the Screening of Uterine Cervical Lesion

Cervical Cancer | Cervical Intraepithelial Neoplasia | DNA Methylation | Cytology | High-risk Human Papillomavirus

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy | High Risk Prostate Cancer | Locally Advanced Prostate Cancer | Intense Endocrine Therapy

China
Advaxis, Inc.
Gynecologic Oncology Group

Terminated

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer (AIM2CERV)

High Risk Cervical Cancer | Advanced Cervical Cancer

United States, Argentina, Brazil, Canada, Chile, Korea, Republic of, Malaysia, Mexico, Poland, Russian Federation, Serbia, Spain, Taiwan, Ukraine
West China Hospital

Recruiting

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Neoadjuvant Chemotherapy | High-risk Locally Advanced Colorectal Cancer | FOLFOXIRI Regimen

China
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
Haaglanden Medical Centre
Tata Memorial Centre

Not yet recruiting

Towards Optimal Treatment for High Risk Prostate Cancer (HYPOPRIME)

High Risk Prostate Carcinoma

Netherlands
FutureChem

Recruiting

Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis

High Risk Prostate Carcinoma

Korea, Republic of
Cairo University

Unknown

Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder Cancer

Urothelial Carcinoma Bladder | High-Risk Cancer

Egypt
Samsung Medical Center

Recruiting

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy and Hormone Therapy With SpaceOAR TM for Patients With High - Risk Localized Prostate Cancer (DESAR-H) (DESAR-H)

High Risk Prostate Carcinoma

Korea, Republic of
University Hospital, Essen
Bristol-Myers Squibb; Advanced Accelerator Applications

Not yet recruiting

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer (NEPI)

Very High Risk Prostate Carcinoma

Germany
Sidney Kimmel Comprehensive Cancer Center at Johns...
Frantz Viral Therapeutics

Completed

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)

Cervical Intraepithelial Neoplasia Grade 2/3 | High-risk HPV (Any Strain)

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

China
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Trans Tasman Radiation Oncology Group

Completed

Assessment of New Radiation Oncology Technologies and Treatments (ANROTAT)

Nasopharyngeal Cancer | Anal Cancer | Intermediate Risk Prostate Cancer | Prostate Cancer (Post Prostatectomy)

Australia
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk

China

Clinical Trials on Local Advanced High Risk Nasopharyngeal Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations